Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings Inc. (symbol: CDIO) is a pioneering biotechnology company focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. Leveraging cutting-edge artificial intelligence, the company has developed a proprietary Genetic-Epigenetic Engine™ designed to revolutionize the management of cardiovascular health.
The main goal of Cardio Diagnostics is to enhance the accuracy and efficacy of cardiovascular disease prevention and treatment. The company's flagship technology integrates genetic and epigenetic data to provide a comprehensive understanding of an individual’s cardiovascular risk, enabling targeted interventions and personalized care plans. This innovative approach aims to reduce the incidence of cardiovascular events and improve patient outcomes.
Recent achievements include expanding their product portfolio and forming strategic partnerships with leading healthcare providers to broaden the reach of their diagnostic tools. The company is also actively involved in research projects aimed at further enhancing their AI-driven platform's capabilities. Financially, Cardio Diagnostics Holdings Inc. has seen steady growth, marked by increasing investor interest and promising market forecasts.
With a dedicated team of experts in genetics, bioinformatics, and clinical research, Cardio Diagnostics continues to push the boundaries of medical technology. Their commitment to advancing cardiovascular healthcare promises significant strides in the early detection and prevention of one of the leading causes of mortality worldwide.
Rhea-AI Summary
Cardio Diagnostics Holdings, an AI-driven precision cardiovascular medicine company (Nasdaq: CDIO), has received a dedicated CPT PLA code, 0439U, from the American Medical Association for its AI-powered coronary heart disease event risk assessment test, Epi+Gen CHD. This milestone will accelerate reimbursement from federal and private payers, increasing access to precision cardiovascular medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has achieved a milestone by obtaining a dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA) code, 0440U, from the American Medical Association (AMA) for its AI-driven coronary heart disease (CHD) detection test, PrecisionCHD. This will facilitate reimbursement from federal and private payers and expand access to the innovative test. The CPT PLA code will be effective on April 1, 2024, and is a significant step toward broader adoption of the first and only integrated genetic-epigenetic diagnostic blood test for CHD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.89%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) appoints Paul Burton, J.D., MBA as Independent Director, bringing over 20 years of experience in medical technology innovation, corporate finance, and shaping the strategy and operations of growth-stage companies. Mr. Burton will Chair the Nominating and Corporate Governance Committee and serve as a member of the Audit Committee. His expertise in healthcare investing, growth strategy, and FDA navigation will be invaluable in advancing Cardio Diagnostics' vision of using advanced diagnostics for more personalized cardiovascular care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring continued listing on The Nasdaq Capital Market. The company's common stock maintained a minimum closing bid price of $1.00 or more for 10 consecutive business days, from November 20, 2023, to December 4, 2023, leading to Nasdaq closing the matter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, a leader in artificial intelligence-driven precision cardiovascular medicine tests, will be attending the 42nd Annual J.P. Morgan Healthcare Conference from January 8 to 11, 2024, in San Francisco, CA. The company's management will be presenting a roundtable session titled 'Operationalizing Value-Based Care in Shared Risk Contracts: A Novel Model for Heart Disease Risk Management' to discuss risk mitigation strategies across the cardiovascular medicine continuum. The roundtable will bring together healthcare stakeholders to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is convening a roundtable at the 42nd Annual J.P. Morgan Healthcare Conference to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space. The company's management will be attending the conference from January 8 to 11, 2024, in San Francisco, CA. The roundtable will bring together healthcare stakeholders to facilitate the development of more robust value-based care models for tackling heart disease risks to support better patient outcomes and innovative payer models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
Rhea-AI Summary
Cardio Diagnostics Holdings, a leader in AI-driven precision cardiovascular medicine tests, announced that the AMA is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes. If approved, the codes are expected to be published by January 1, 2024, and will be effective on April 1, 2024. This move would be a significant step towards securing federal and private payer reimbursement for the tests, streamlining the reimbursement process and facilitating broader adoption of Cardio's next-generation cardiovascular tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) announced the publication of a groundbreaking study in the Journal of the American Heart Association (JAHA) detailing the development and validation of PrecisionCHD, an artificial intelligence-guided integrated genetic-epigenetic test for detecting coronary heart disease (CHD). The test, a blood-based alternative to invasive and costly traditional methods, uses AI and personalized genetic and epigenetic information to sensitively detect CHD. The study, conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics, involved 2,516 individuals and marks a significant leap in CHD diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
123.23%
Tags
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. and Family Medicine Specialists announce a partnership to implement advanced blood-based tests to identify patients at risk for coronary heart disease (CHD) events, aiming to prevent heart attacks and reduce treatment costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
102.94%
Tags
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc has received an Innovation Technology contract from Vizient, Inc. The contract allows Vizient's customer base, which includes over 60% of hospitals and 97% of academic medical centers in the US, to access Cardio Diagnostics' AI-driven molecular heart disease tests at negotiated pricing. The tests utilize a proprietary AI algorithm to analyze objective epigenetic and genetic biomarkers in patients suspected to be at risk or who may have coronary heart disease. This contract signifies recognition of Cardio Diagnostics' mission to transform cardiovascular disease management through advanced diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.78%
Tags
FAQ
What is the current stock price of Cardio Diagnostics Holdings (CDIO)?
The current stock price of Cardio Diagnostics Holdings (CDIO) is $0.255 as of November 15, 2024.
What is the market cap of Cardio Diagnostics Holdings (CDIO)?
The market cap of Cardio Diagnostics Holdings (CDIO) is approximately 7.3M.
What does Cardio Diagnostics Holdings Inc. do?
Cardio Diagnostics Holdings Inc. specializes in cardiovascular disease prevention and early detection using a proprietary Genetic-Epigenetic Engine™ driven by artificial intelligence.
What is the Genetic-Epigenetic Engine™?
The Genetic-Epigenetic Engine™ integrates genetic and epigenetic data to provide a precise understanding of cardiovascular risk and facilitate personalized care.
What are the recent achievements of Cardio Diagnostics Holdings Inc.?
Recent achievements include expanding their product portfolio and forming strategic partnerships with leading healthcare providers.
How does Cardio Diagnostics' technology benefit patients?
Their technology allows for early detection and personalized prevention of cardiovascular disease, improving patient outcomes and reducing health risks.
Are there any ongoing research projects at Cardio Diagnostics?
Yes, the company is actively involved in research to further enhance the capabilities of their AI-driven platform.
What is the financial outlook for Cardio Diagnostics Holdings Inc.?
The company has seen steady financial growth with increasing investor interest and promising market forecasts.
What makes Cardio Diagnostics' approach unique?
Their integration of genetic and epigenetic data using artificial intelligence offers a highly precise and personalized approach to cardiovascular care.
Who are the key partners of Cardio Diagnostics?
Cardio Diagnostics has formed strategic partnerships with leading healthcare providers to expand the reach of their diagnostic tools.
What is the company's mission?
The company's mission is to make cardiovascular disease prevention and detection more accessible, personalized, and effective.
Where is Cardio Diagnostics Holdings Inc. based?
Further company details like location are available on their official website and financial reports.
Cardio Diagnostics Holdings Inc.
Nasdaq:CDIO
CDIO Rankings
CDIO Stock Data
7.34M
25.91M
13.03%
5.92%
3.35%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
United States of America
CHICAGO